Difference between revisions of "Team:ETH Zurich"

Revision as of 10:09, 8 October 2017

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.

Learn more

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description

CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor

The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.

Design

@@ Line 11: / Line 11: @@
      $('a[href*=#]').on('click', function(e) {
      e.preventDefault();
-     $('html, body').animate({ scrollTop: $($(this).attr('href')).offset().top}, 500, 'linear');
+     $('html, body').animate({ scrollTop: $($(this).attr('href')).offset().top}, 300, 'linear');
      });
      });